Literature DB >> 33483615

T-ALL can evolve to oncogene independence.

Hesham Abdulla1, Anh Vo2, Benjamin J Shields2, Tenae J Davies2, Jacob T Jackson1,2, Raed Alserihi1,3, Elizabeth M Viney1, Tin Wong2, Feng Yan2,4, Nicholas C Wong2,4, Lisa Demoen5,6, David J Curtis2, Warren S Alexander1,7, Pieter Van Vlierberghe5,6, Ross A Dickins2, Matthew P McCormack8.   

Abstract

The majority of cases of T-cell acute lymphoblastic leukemia (T-ALL) contain chromosomal abnormalities that drive overexpression of oncogenic transcription factors. However, whether these initiating oncogenes are required for leukemia maintenance is poorly understood. To address this, we developed a tetracycline-regulated mouse model of T-ALL driven by the oncogenic transcription factor Lmo2. This revealed that whilst thymus-resident pre-Leukemic Stem Cells (pre-LSCs) required continuous Lmo2 expression, the majority of leukemias relapsed despite Lmo2 withdrawal. Relapse was associated with a mature phenotype and frequent mutation or loss of tumor suppressor genes including Ikzf1 (Ikaros), with targeted deletion Ikzf1 being sufficient to transform Lmo2-dependent leukemias to Lmo2-independence. Moreover, we found that the related transcription factor TAL1 was dispensable in several human T-ALL cell lines that contain SIL-TAL1 chromosomal deletions driving its overexpression, indicating that evolution to oncogene independence can also occur in human T-ALL. Together these results indicate an evolution of oncogene addiction in murine and human T-ALL and show that loss of Ikaros is a mechanism that can promote self-renewal of T-ALL lymphoblasts in the absence of an initiating oncogenic transcription factor.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2021        PMID: 33483615     DOI: 10.1038/s41375-021-01120-9

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

1.  The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Martine van Grotel; H Berna Beverloo; Charles Lee; Tryggvi Helgason; Jessica Buijs-Gladdines; Monique Passier; Elisabeth R van Wering; Anjo J P Veerman; Willem A Kamps; Jules P P Meijerink; Rob Pieters
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.

Authors:  Lili Wu; Yang Xu; Qian Wang; Changgeng Ruan; Hans G Drexler; Depei Wu; Roderick A F MacLeod; Suning Chen
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  [Homology of the peroneal muscles and the foot muscles (M. extensor hallucis and M. extensor digitorum brevis)].

Authors:  A Kaneff
Journal:  C R Assoc Anat       Date:  1970-09

Review 4.  Conditional mouse models of sporadic cancer.

Authors:  Jos Jonkers; Anton Berns
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

Review 5.  Genetic Basis of Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 6.  Oncogene addiction: sometimes a temporary slavery.

Authors:  Jos Jonkers; Anton Berns
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

7.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

8.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

9.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Authors:  Asa Karlsson; Sylvie Giuriato; Flora Tang; Jingly Fung-Weier; Göran Levan; Dean W Felsher
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

10.  LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.

Authors:  Dragan Jevremovic; Anja C Roden; Rhett P Ketterling; Paul J Kurtin; Ellen D McPhail
Journal:  Am J Clin Pathol       Date:  2016-01-21       Impact factor: 2.493

View more
  1 in total

1.  Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma.

Authors:  Chang-Lung Lee; David G Kirsch; Kennedy D Brock; Stephanie Hasapis; Dadong Zhang; Alexander B Sibley; Xiaodi Qin; Jeremy S Gresham; Isibel Caraballo; Lixia Luo; Andrea R Daniel; Matthew J Hilton; Kouros Owzar
Journal:  Cancer Res       Date:  2021-05-25       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.